<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00956150</url>
  </required_header>
  <id_info>
    <org_study_id>HRRC 07-155</org_study_id>
    <nct_id>NCT00956150</nct_id>
  </id_info>
  <brief_title>Bacterial Overgrowth Associated With Chronic Multisymptom Illness Complex</brief_title>
  <official_title>Bacterial Overgrowth Associated With Chronic Multisymptom Illness Complex</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henry C. Lin, MD</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New Mexico VA Healthcare System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The adverse impact of Gulf War Syndrome (GWS) on the health of veterans and on the resources
      of the VA Healthcare System underscores the need to resolve its underlying cause. In
      response, the investigators propose to investigate the central hypothesis that gut bacteria
      may be responsible for symptoms associated with GWS. The investigators will enroll a total of
      120 patients with GWS and 90 healthy controls.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigator will assess the prevalence and role of abnormal gut microbial fermentation
      among Veterans with GWS and investigate the efficacy of diagnostic and treatment strategies
      directed at indigenous gut microbes in the management of GWS.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2009</start_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the pattern of bacterial gas excretion in breath among Veterans with Gulf War Syndrome vs. Controls using Lactulose Breath Test</measure>
    <time_frame>every 15 minutes for 180 minutes</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine the response to antibiotic treatment in Gulf War Syndrome patients.</measure>
    <time_frame>Two weeks</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Gulf War Syndrome</condition>
  <arm_group>
    <arm_group_label>60 GWS Rifaximin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>60 GWS Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient is a healthy control and will not be on study intervention. Asked to perform Lactulose Breath Test to compare results with GWS patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lactulose Breath Test</intervention_name>
    <description>Test will begin with a baseline breath sample followed by ingestion of 10g of lactulose (Xactdose, South Beloit, IL) in 100ml of water. Breath samples will be collected every 15 min for 180 min. Gas samples will be analyzed for hydrogen and methane using a gas chromatograph (Model SC, Quintron Instruments, Milwaukee, WI).</description>
    <arm_group_label>60 GWS Rifaximin</arm_group_label>
    <arm_group_label>60 GWS Placebo</arm_group_label>
    <arm_group_label>Healthy Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifaximin</intervention_name>
    <description>Rifaximin 600 mg three times a day by mouth (TID PO) x 10 days</description>
    <arm_group_label>60 GWS Rifaximin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo TID PO x 10 days</description>
    <arm_group_label>60 GWS Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gulf War Veterans meeting the 1994 Centers for Disease Control and Prevention (CDC)
             criteria for the diagnosis of Chronic Fatigue Syndrome(CFS), i.e &gt; six months of one
             or more symptoms from at least two of the following three clusters: general fatigue,
             mood and cognitive abnormalities, and musculoskeletal pain

          -  Must be under the care of a primary physician and have had a previous diagnosis of
             Gulf War-related illness or GWS and have medical records documenting investigations to
             rule out other causes of fatigue

          -  Minimum of the following laboratory screening tests: complete blood count with
             leukocyte differential, erythrocyte sedimentation rate, serum electrolytes, calcium,
             glucose, blood urea nitrogen, creatinine,urinalysis, and thyroid function tests

          -  Subjects must also have a GI consult first as part of routine care to confirm
             eligibility and availability

          -  Patients with Irritable Bowel Syndrome (IBS), fibromyalgia (FM), anxiety or depression
             will not be excluded, but will be identified for subgroup analysis

          -  Healthy controls will be screened with complete blood count (CBC) and comprehensive
             metabolic panel to confirm eligibility

        Exclusion Criteria:

          -  History of peptic ulcer, inflammatory bowel disease, diabetes, cirrhosis, rheumatoid
             arthritis, lupus, narcotic dependence,celiac disease, tropical sprue, bowel
             resection(including gastric, small bowel or colon; but gallbladder surgery or
             appendectomy are NOT exclusion criteria)

          -  Patients with chronic illness (HIV, tuberculosis)

          -  Pregnant or breast-feeding, psychotic depression, bipolar disorder, schizophrenia,
             eating disorders

          -  Healthy subjects will be excluded if their questionnaire indicated abnormal symptom
             profile
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Natalie R Mills, BS</last_name>
    <phone>505-265-1711</phone>
    <phone_ext>2286</phone_ext>
    <email>Natalie.Mills@va.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Henry C Lin, MD</last_name>
    <phone>505-265-1711</phone>
    <phone_ext>4511</phone_ext>
    <email>helin@salud.unm.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>New Mexico VA Healthcare System</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie R Mills, BS</last_name>
      <phone>505-265-1711</phone>
      <phone_ext>2286</phone_ext>
      <email>Natalie.Mills@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Henry C Lin, MD</last_name>
      <phone>505-265-1711</phone>
      <phone_ext>4511</phone_ext>
      <email>helin@salud.unm.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Henry C Lin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2009</study_first_submitted>
  <study_first_submitted_qc>August 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2009</study_first_posted>
  <last_update_submitted>April 30, 2013</last_update_submitted>
  <last_update_submitted_qc>April 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>New Mexico VA Healthcare System</investigator_affiliation>
    <investigator_full_name>Henry C. Lin, MD</investigator_full_name>
    <investigator_title>Henry C. Lin, MD</investigator_title>
  </responsible_party>
  <keyword>Chronic Multisymptom Complex</keyword>
  <keyword>Small Intestinal Bacterial Overgrowth</keyword>
  <keyword>Gulf War Syndrome</keyword>
  <keyword>Chronic Multisymptom Illness Complex</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Persian Gulf Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifaximin</mesh_term>
    <mesh_term>Lactulose</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

